Compare DARE & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DARE | BCTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Canada |
| Employees | 24 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 28.8M |
| IPO Year | 2014 | 2025 |
| Metric | DARE | BCTX |
|---|---|---|
| Price | $2.36 | $3.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $10.00 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 769.5K | 217.5K |
| Earning Date | 05-14-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,807,885.00 | N/A |
| Revenue This Year | $2,115.12 | N/A |
| Revenue Next Year | $122.62 | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $0.61 |
| 52 Week High | $9.19 | $14.68 |
| Indicator | DARE | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 40.60 |
| Support Level | $1.79 | $2.98 |
| Resistance Level | $2.54 | $4.51 |
| Average True Range (ATR) | 0.35 | 0.30 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 22.28 | 33.09 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.